Drug Profile


Alternative Names: BBR 3438

Latest Information Update: 18 Nov 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novuspharma; University of Vermont
  • Developer Novuspharma
  • Class Anthraquinones; Antineoplastics; Pyrazolones; Small molecules
  • Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Gastric cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 18 Nov 2002 Discontinued - Phase-II for Gastric cancer in Europe (IV)
  • 18 Nov 2002 Discontinued - Phase-II for Gastric cancer in Germany (unspecified route)
  • 18 Nov 2002 Discontinued - Phase-II for Ovarian cancer in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top